Phenotypes associated with this allele
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Oprm1tm1Jep mutation
(0 available);
any
Oprm1 mutation
(53 available)
|
|
|
behavior/neurological
|
• following treatment with amphetamine, mice exhibit a greater increase in locomotor activity compared with similarly treated wild-type mice
|
|
• 2.5 hours before food access, mice exhibit a reduced increased in running wheel activity prior to food access (food anticipitory behavior) compared with similarly treated wild-type mice
• during the 3 hours feeding period, mice exhibit a lower decrease in running wheel activity compared with similarly treated wild-type mice
|
|
• following treatment with amphetamine, mice exhibit a greater increase in locomotor activity compared with similarly treated wild-type mice
|
nervous system
|
• midbrain dopamine neurons exhibit lower firing rates and non-bursting activity compared to in wild-type mice with fewer neurons exhibiting fast firing rates
• unlike in wild-type mice, one third of neurons display no bursting at all
• however, the quality of bursting size, burst duration, and frequency of pikes within bursts are normal
|
adipose tissue
|
• fat tissue is increased 73% compared to in wild-type mice
|
|
• mice exhibit a 5% increased in fat as a percentage of body composition compared with wild-type mice
|
homeostasis/metabolism
growth/size/body
|
• while mice exhibit a 11% increase in lean tissue this results is a 5% decrease in lean tissue as a percent of whole body composition compared with wild-type mice
|
|
• mice exhibit increased body weight compared with wild-type mice except at birth and during the weaning period (2 to 4 weeks)
|
endocrine/exocrine glands
|
• mice exhibit a 50% increase in pancreas insulin content compared with wild-type mice
• glucose- and tolbutamide-mediated insulin secretion is increased compared to in wild-type islets
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Oprm1tm1Jep mutation
(0 available);
any
Oprm1 mutation
(53 available)
|
|
|
behavior/neurological
|
• in a tail flick assay, mice treated with morphine, methadone, or DAMGO display nearly no analgesic response unlike in similarly treated wild-type mice
(J:52952)
• however, analgesic response to U50,488H, naloxone benzoylhydrazone (NalBzoH), morphine-6beta-glucuronide (M6G), heroine, 6-acetyl-morphine, and D-Penicillamine(2,5)-enkephalin (DPDPE) is normal
(J:52952)
• morphine analgesic response is abolished unlike in wild-type mice
(J:65217)
|
|
• improgan analgesic response is enhanced in female mice compared to in wild-type mice
• however, improgan analgesia in males is normal
|
|
• in a tail flick assay, mice treated with morphine, methadone, or DAMGO display nearly no analgesic response unlike in similarly treated wild-type mice
(J:52952)
• however, analgesic response to U50,488H, naloxone benzoylhydrazone (NalBzoH), morphine-6beta-glucuronide (M6G), heroine, 6-acetyl-morphine, and D-Penicillamine(2,5)-enkephalin (DPDPE) is normal
(J:52952)
• morphine analgesic response is abolished unlike in wild-type mice
(J:65217)
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Oprm1tm1Jep mutation
(0 available);
any
Oprm1 mutation
(53 available)
|
|
|
behavior/neurological
|
• following treatment with amphetamine, mice exhibit a greater increase in locomotor activity compared with similarly treated wild-type mice
|
|
• during the 3 hours feeding period, mice exhibit a lower decrease running wheel activity compared with similarly treated wild-type mice
|
|
• following treatment with amphetamine, mice exhibit a greater increase in locomotor activity compared with similarly treated wild-type mice
|
Allelic Composition |
Oprm1tm1Jep/Oprm1+
|
|
Genetic Background |
involves: 129S/SvEv |
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Oprm1tm1Jep mutation
(0 available);
any
Oprm1 mutation
(53 available)
|
|
|
behavior/neurological
|
• in a tail flick assay, mice exhibit an intermediate analgesic response following morphine, methadone, or DAMGO treatment compared with wild-type and homozygous mice
(J:52952)
• however, analgesic response to U50,488H, naloxone benzoylhydrazone (NalBzoH), morphine-6beta-glucuronide (M6G), heroine, 6-acetyl-morphine, and D-Penicillamine(2,5)-enkephalin (DPDPE) is normal
(J:52952)
• morphine analgesic response is attenuated compared to in wild-type mice
(J:65217)
|
|
• improgan analgesic response is enhanced in female mice compared to in wild-type mice
• however, improgan analgesia in males is normal
|
|
• in a tail flick assay, mice exhibit an intermediate analgesic response following morphine, methadone, or DAMGO treatment compared with wild-type and homozygous mice
(J:52952)
• however, analgesic response to U50,488H, naloxone benzoylhydrazone (NalBzoH), morphine-6beta-glucuronide (M6G), heroine, 6-acetyl-morphine, and D-Penicillamine(2,5)-enkephalin (DPDPE) is normal
(J:52952)
• morphine analgesic response is attenuated compared to in wild-type mice
(J:65217)
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Oprd1tm1Jep mutation
(0 available);
any
Oprd1 mutation
(29 available)
Oprm1tm1Jep mutation
(0 available);
any
Oprm1 mutation
(53 available)
|
|
|
behavior/neurological
N |
• mice exhibit normal nociception prior to opioid infusion
|
|
• unlike in wild-type mice, mice exhibit decreased tail-withdrawal latencies demonstrating the abolishment of opioid analgesic responses to acute doses of morphine and oxymorphone
• infusion of morphine results in a decrease in tail withdrawal latency relative to baseline after 2 days unlike similarly treated wild-type mice that display an increase on the first two days and a decrease on days 4 through 7
• infusion of oxymorphone results in reduced tail withdrawal latency compared to baseline at 4 days unlike in similarly treated wild-type mice that exhibit an increase in latency within the first 4 days and a decrease on days 8 through 10
• NMDA receptor blockage with MK-801 does not reverse opioid hyperalgesia unlike in similarly treated wild-type mice
|
|
• unlike in wild-type mice, mice exhibit decreased tail-withdrawal latencies demonstrating the abolishment of opioid analgesic responses to acute doses of morphine and oxymorphone
• infusion of morphine results in a decrease in tail withdrawal latency relative to baseline after 2 days unlike similarly treated wild-type mice that display an increase on the first two days and a decrease on days 4 through 7
• infusion of oxymorphone results in reduced tail withdrawal latency compared to baseline at 4 days unlike in similarly treated wild-type mice that exhibit an increase in latency within the first 4 days and a decrease on days 8 through 10
• NMDA receptor blockage with MK-801 does not reverse opioid hyperalgesia unlike in similarly treated wild-type mice
|
homeostasis/metabolism
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Arrb2tm1Rjl mutation
(2 available);
any
Arrb2 mutation
(27 available)
Oprm1tm1Jep mutation
(0 available);
any
Oprm1 mutation
(53 available)
Tg(Th-Oprm1)4Jtw mutation
(1 available)
|
|
|
nervous system
N |
• desensitization and internalization of opioid receptors after met-enkephalin treatment is similar to that in controls
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Oprm1tm1Jep mutation
(0 available);
any
Oprm1 mutation
(53 available)
Tg(Th-Oprm1)4Jtw mutation
(1 available)
|
|
|
nervous system
N |
• maximum hyperpolarization of neurons induced by met-enkephalin (ME) is similar to that seen in wild-type and transgenic wild-type opioid receptor mutant animals; the EC50 for ME is 50% greater than the transgene-only mutants
• desensitization by ME and recovery of desensitization of receptors is similar to wild-type and transgene-only controls
• desensitization and internalization of the mu-opioid receptor (MOR) in response to various MOR agonists is not different in mutants and controls
|